Detection of a second malignancy in prostate cancer patients by using [18F]Choline PET/CT: a case series

Cancer Imaging

Table 1 Baseline patients characteristics and main results

Pt	Age, years	Curative PCa treatment(s)	PSA (ng/mL)	PET/CT			Final diagnosis	Treatment
Pt	Age, years	Curative PCa treatment(s)	PSA (ng/mL)	Year	Clinical purpose	[¹⁸F]Fluorocholine uptake (site)	Final diagnosis	Expected	Undertaken
#1	72	RP (2004) + ADT (ongoing)	0.11	2010	Diagnosis of incidental bone lesion (PCa mts ?)	Lung + bone and soft tissues	NSCLC	CHT (docetaxel)	CHT (platinum-based) + palliative EBRT
#2	71	RP (1998) + salvage EBRT (2009)	0.08	2010	Persistence of increased PSA after salvage EBRT	Lung	NSCLC	ADT	CHT (platinum-based)
#3	84	EBRT (1996)	2.62	2008	Biochemical recurrence	Lung + lymph nodes	NSCLC	ADT +/− salvage EBRT	Follow-up (patient refused any treatment)
#4	80	RP (2003)	8.77	2014	Biochemical recurrence	Lymph node	Melanoma	ADT +/− salvage EBRT	Excision of melanoma metastases
#5	71	EBRT (2003) + ADT (stopped)	3.16	2012	Biochemical recurrence	Lung	NSCLC	Salvage EBRT	Lung lobectomy + salvage EBRT
#6	74	RP (2012)	1.4	2012	Persistence of increased PSA after RP	Lung	NSCLC	ADT	Lung lobectomy + salvage EBRT
#7	80	RP (2012) + ADT (stopped)	0.3	2013	Biochemical recurrence	Rectum	Colorectal cancer	ADT +/− salvage EBRT	Anterior resection of rectum + ADT

ADT androgen deprivation therapy, EBRT external beam radiation therapy, CHT chemotherapy, NSCLC non small cell lung cancer, PCa prostate cancer, PSA prostate serum antigen, Pt patient, RP radical prostatectomy

ISSN: 1470-7330